EUFLEXXA®

Order EUFLEXXA® Online

EUFLEXXA® injection is an FDA-approved non-avian sodium hyaluronate viscosupplement for knee pain due to osteoarthritis in patients who have not achieved adequate relief from conservative therapy or simple analgesics. Each prefilled syringe delivers 20 mg of biofermentation-derived hyaluronan in 2 mL, given as a course of three consecutive weekly intra-articular injections to the knee. Licensed practitioners can buy EUFLEXXA® online through Medical Spa Rx with secure checkout and both individual and bulk ordering. Order EUFLEXXA® knee injection below, or browse the wider range of orthopedic viscosupplements stocked on the platform.

Why Practitioners Choose EUFLEXXA® Over Other Viscosupplements

• Non-Avian Sourcing: EUFLEXXA® is produced through bacterial biofermentation and contains no avian-derived proteins, unlike HYALGAN®, SUPARTZ®, and SYNVISC®, all of which are avian-derived and carry contraindications for patients with avian protein sensitivities per their respective labeling [2][3]. In practice this removes a screening step. Practitioners can offer EUFLEXXA® injections without first establishing avian sensitivity status, which matters more in high-volume clinics than the eligibility difference alone would suggest.
• Established Billing Infrastructure: EUFLEXXA® knee injection carries a product-specific HCPCS code, J7323, alongside a defined CPT pathway for the injection procedure, and manufacturer-sponsored copay assistance may be available to eligible patients through Ferring Pharmaceuticals [5]. Dedicated coding and patient support reduce the administrative load for practices running several viscosupplement products through the same reimbursement workflow.

About EUFLEXXA® — Non-Avian HA Viscosupplementation

EUFLEXXA® holds FDA Premarket Approval under PMA P010029/S008, approved October 11, 2011, building on an original 2004 approval of the predecessor device [4]. It is classified as an intra-articular medical device rather than a pharmaceutical, with sodium hyaluronate as its active component [4].

The approved indication covers knee pain associated with osteoarthritis in adults who have not achieved adequate relief from conservative non-pharmacologic measures and simple analgesics such as acetaminophen [4]. The pivotal FLEXX Trial demonstrated a statistically significant reduction in pain compared with placebo [1].

Manufacturing is what sets the product apart at the category level. EUFLEXXA® is produced through bacterial fermentation of Streptococcus equi, which makes it non-avian and free of animal-derived proteins, and removes any question of avian protein exposure for eligible patients [1][4].

EUFLEXXA® Technology — Non-Avian HA and Molecular Weight

EUFLEXXA® is a sterile, viscoelastic solution of highly purified sodium hyaluronate dissolved in phosphate-buffered saline [4]. Published analyses report its molecular weight at approximately 2,400 to 3,600 kDa, placing it among the non-cross-linked intra-articular HA products available in the United States [2]. Each 1 mL contains 10 mg of sodium hyaluronate along with sodium chloride, phosphate buffers, and water for injection [4].

In healthy joints, endogenous hyaluronan works as both lubricant and shock absorber. Osteoarthritis depletes both the concentration and the molecular weight forms of hyaluronan present, which reduces the viscoelastic properties of synovial fluid and contributes to pain and restricted movement [2][3]. EUFLEXXA® supplements that depleted hyaluronan to help restore the joint’s lubricating and cushioning environment. A peer-reviewed rheological comparison found that EUFLEXXA® approximated healthy synovial fluid across several measured parameters, including molecular structure and shear behavior [2].

EUFLEXXA® is not a steroid. It is a purified hyaluronic acid medical device containing no pharmacologically active anti-inflammatory agents, and its therapeutic effect is mechanical rather than pharmacologic [4].

At Medical Spa Rx, we stock HA across both orthopedic and aesthetic applications, and practitioners who buy HA dermal fillers are working with the same foundational chemistry they encounter in intra-articular products. Clinics running aesthetic alongside orthopedic services can buy dermal fillers from the same catalog on a single order.

About the EUFLEXXA® Manufacturer

EUFLEXXA® is manufactured by Ferring Pharmaceuticals, Inc., part of a global biopharmaceutical organization headquartered in Saint-Prex, Switzerland [4]. EUFLEXXA® is its viscosupplementation offering for knee osteoarthritis.

Clinics looking to buy EUFLEXXA® wholesale should confirm current distributor channels and supply agreements, since commercial partnerships and regional availability both change over time.

EUFLEXXA® Product Spotlight

EUFLEXXA® 20 mg/2 mL prefilled syringe, supplied as a pack of three, delivers 20 mg of sodium hyaluronate in 2 mL of phosphate-buffered saline at a 1% concentration of 10 mg/mL [4]. Sodium hyaluronate is the EUFLEXXA® generic name. Produced via bacterial biofermentation without avian-derived materials, it comes as a sterile, viscoelastic solution in a disposable, single-use prefilled glass syringe [4]. The full treatment course runs to three weekly intra-articular injections, one syringe per session per knee, which makes the three-pack the natural procurement unit for a single treatment cycle [1].

Licensed practitioners can purchase EUFLEXXA® wholesale through Medical Spa Rx, with bulk and individual ordering both available. Clinics stocking a wider intra-articular range can also buy orthopedic injections from the full catalog.

Buy EUFLEXXA® Wholesale — Pricing and Order Quantities

EUFLEXXA® injection cost is best assessed per treatment course rather than per syringe, since the approved protocol runs to three weekly injections and a partial course does not deliver the studied outcome. One three-pack treats one knee through a full cycle, which makes the pack the practical unit for both budgeting and stock planning. Bilateral treatment doubles the requirement.

Reimbursement changes the arithmetic further. Because J7323 is a per-dose HCPCS code, a clinic recovering cost through billing is working from a different net figure than one quoting a patient directly, and EUFLEXXA® copay assistance through Ferring may shift the patient-facing number again where eligibility applies. Practices comparing EUFLEXXA® injection cost against avian-derived alternatives should run the comparison across a full course at their own reimbursement rate rather than against list price per unit.

Licensed practitioners can buy EUFLEXXA® wholesale through Medical Spa Rx, with bulk pricing on multi-pack quantities and individual three-packs available for lower-volume practices. Add-to-cart ordering and secure checkout mean a clinic can purchase EUFLEXXA® online without a quote request or account manager call, which for a single-course order is usually the difference between ordering today and ordering next week.

Treatment Areas and Patient Indications

EUFLEXXA® is indicated for adults with knee osteoarthritis who have not achieved adequate relief from conservative non-pharmacologic therapy or simple analgesics [4]. It functions as a non-surgical pain management option for patients who are not yet candidates for arthroscopic procedures or total knee replacement, or who want to postpone them.

The FLEXX Trial enrolled men and women aged 40 or older with chronic knee OA confirmed by ACR criteria, radiographic evidence of Kellgren-Lawrence grade 2 or 3 disease, and moderate to severe pain on a standardized walking assessment [1]. For patients with a history of avian protein sensitivity, the non-avian biofermentation source makes EUFLEXXA® directly relevant where several competing products are not [1][4]. Patients with knee joint infection, skin disease at the injection site, or known hypersensitivity to hyaluronan preparations fall outside the approved indication [4].

Administration and EUFLEXXA® Injection Protocol

EUFLEXXA® is given as a single intra-articular injection into the knee joint per session by a qualified healthcare professional using strict aseptic technique [1][4]. EUFLEXXA® dosage is fixed at 20 mg in 2 mL per injection, so the variable practitioners work with is the course rather than the individual dose. The standard schedule is three consecutive weekly EUFLEXXA® injections, and any joint effusion should be aspirated before injecting, which supports accurate product placement and patient comfort [4].

Two handling points are easy to miss. Practitioners should avoid skin disinfectants containing quaternary ammonium salts such as benzalkonium chloride, since these can cause hyaluronan precipitation [4]. And each syringe is single-use, so bilateral knee treatment requires a separate sterile syringe for each joint [4][5]. EUFLEXXA® must not be injected intravascularly or into any joint other than the knee [4].

On how long it takes for EUFLEXXA® to work, clinical improvement builds progressively across the three-injection course and the weeks that follow rather than arriving at a single point. The FLEXX Trial assessed outcomes through 26 weeks post-first injection, with pain improvements recorded at multiple timepoints across that window [1]. Response varies with osteoarthritis severity, patient age, body weight, and overall clinical profile.

EUFLEXXA® Shipping, Storage, and Handling

EUFLEXXA® is supplied in single-use prefilled glass syringes and should be stored per the conditions stated in current labeling, with practitioners working from the IFU supplied with the shipment rather than from general viscosupplement guidance [4]. Syringes should be protected from freezing and kept in the original carton until use.

Shipping for intra-articular products warrants the same receiving discipline any injectable does. Clinics should inspect cartons on arrival, confirm the syringe barrels are intact and the solution is clear, and check that quantities and lot numbers match the documentation before stock goes into the treatment room. A syringe showing particulate matter, discoloration, or damage to the barrel or plunger should not be used.

EUFLEXXA® shipping arrangements and in-clinic handling feed the same outcome: product that reaches the joint in the condition the trial data assumed.

Comparing EUFLEXXA® to Other Viscosupplements

EUFLEXXA® vs ORTHOVISC®

EUFLEXXA® and ORTHOVISC® are both non-avian, bacterially fermented, non-cross-linked sodium hyaluronate viscosupplements [2][3]. The primary distinction is molecular weight: EUFLEXXA® is reported at approximately 2,400–3,600 kDa while ORTHOVISC® is reported at approximately 1,000–2,900 kDa in published analyses [2]. ORTHOVISC® offers a four-injection course compared with EUFLEXXA®’s three-injection schedule, and clinics wanting both options on hand can buy ORTHOVISC® through the same catalog [3].

EUFLEXXA® vs MONOVISC®

MONOVISC® is a cross-linked hyaluronic acid viscosupplement designed for single-injection delivery, whereas EUFLEXXA® is administered as three weekly injections [2][3]. Both are non-avian and produced via bacterial fermentation, but their molecular structures differ: EUFLEXXA® retains a linear-chain configuration closer to that of native hyaluronan, while practices serving patients who prefer fewer visits can buy MONOVISC® alongside their EUFLEXXA® stock [2].

EUFLEXXA® vs HYALGAN®

HYALGAN® is an avian-derived sodium hyaluronate with a lower reported molecular weight range than EUFLEXXA® and is typically administered over five weekly injections [2][3]. As an avian-sourced product, it carries contraindications for patients with avian protein sensitivities per its labeling, a concern that EUFLEXXA® avoids through its non-avian biofermentation manufacturing [2][3]. Clinics keeping a multi-injection avian option in stock can buy HYALGAN® through Medical Spa Rx.

EUFLEXXA® vs SYNVISC®

SYNVISC® (hylan G-F 20) is an avian-derived, chemically cross-linked hylan product with a gel-like consistency that differs from EUFLEXXA®’s linear hyaluronan structure [2]. Its avian source means it carries contraindications for patients with avian protein sensitivities per its labeling, whereas EUFLEXXA®’s non-avian biofermentation process avoids this, and practitioners can buy SYNVISC® where a cross-linked hylan product suits the case [2][3].

EUFLEXXA® vs SUPARTZ®

SUPARTZ® is an avian-derived sodium hyaluronate with a lower reported molecular weight than EUFLEXXA®, typically administered over three to five weekly injections [2][3]. Like HYALGAN®, it carries contraindications for patients with avian protein sensitivities per its labeling. Where that sensitivity is present or unconfirmed, EUFLEXXA® is the straightforward substitution at a comparable course length, though practices stocking both can buy SUPARTZ®.

Regulatory Status and Billing

EUFLEXXA® holds FDA Premarket Approval under PMA P010029/S008, approved October 11, 2011, with the original predecessor device approval dating to December 3, 2004 [4]. The FDA’s Center for Devices and Radiological Health regulates it as a Class III medical device rather than as a pharmaceutical [4].

For billing, the product-specific HCPCS code is J7323, described as “Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose” [5]. This is a per-dose code, so bilateral administration is reported as two units. The injection procedure itself is reported under CPT code 20610 without ultrasound guidance, or 20611 where ultrasound guidance with permanent recording and reporting is used [5]. Where aspiration and injection happen in the same session, only one unit of the procedure code is billable per knee [5]. The correct CPT code for EUFLEXXA® administration depends on whether imaging guidance is used, so practitioners should confirm current HCPCS and CPT guidance and payer policies with the applicable Medicare Administrative Contractor before submitting claims [5].

Manufacturer-sponsored EUFLEXXA® copay assistance may be available to eligible patients through Ferring Pharmaceuticals. Program terms, eligibility criteria, and enrollment requirements all change, so practitioners and patients should contact Ferring directly to verify what currently applies.

EUFLEXXA® Safety Profile — Side Effects and Contraindications

The safety profile was evaluated in the FLEXX Trial across 588 patients and in an open-label extension that followed 433 patients through a repeat treatment course of up to 52 weeks [1]. The product was generally well tolerated, with adverse events consistent with what intra-articular injection procedures and osteoarthritis management would be expected to produce [1].

Commonly reported EUFLEXXA® side effects include arthralgia, joint swelling, and transient injection-site discomfort, alongside non-joint events such as back pain, headache, and upper respiratory tract infection recorded across the trial population [1]. As with any intra-articular injection, temporary pain or swelling at the treated joint may follow administration [1]. On EUFLEXXA® long-term side effects, the open-label extension identified no significant new or worsening safety concerns beyond expected injection-site reactions through 52 weeks [1]. Repeated exposure carries a theoretical potential to elicit an immune response, though clinical studies have not confirmed this [1].

EUFLEXXA® injection is contraindicated in patients with known hypersensitivity to hyaluronan preparations, active knee joint infection, and skin disease or infection at the injection site [4]. It must not be administered intravascularly, into joints other than the knee, or through equipment exposed to benzalkonium chloride-containing solutions [4]. Use in pregnant women, breastfeeding women, and pediatric patients is not established, and practitioners should consult current labeling before treating these populations [4].

FAQs

What is EUFLEXXA®?

EUFLEXXA® injection is an FDA-approved non-avian sodium hyaluronate viscosupplement, supplied at 20 mg/2 mL per prefilled syringe and administered over three consecutive weekly intra-articular knee injections [1][4]. Sodium hyaluronate is used to relieve knee pain due to osteoarthritis in patients who have not responded adequately to conservative therapy or simple analgesics.

Is EUFLEXXA® a steroid?

No. EUFLEXXA® gel injection is a purified, biofermentation-derived sodium hyaluronate medical device containing no corticosteroids [4]. Its mechanism is mechanical rather than pharmacological, restoring viscoelastic properties to synovial fluid depleted by osteoarthritis.

What is EUFLEXXA®’s generic name?

Sodium hyaluronate. EUFLEXXA® is produced via bacterial biofermentation using Streptococcus equi, which makes it non-avian and free of animal-derived proteins [1][4].

How long does it take for EUFLEXXA® to work?

Pain relief builds progressively across the three-injection course and the weeks after it. The FLEXX Trial assessed outcomes through 26 weeks post-first injection, with improvements recorded at multiple timepoints [1]. Individual timelines vary with disease severity and patient factors.

What is the success rate of EUFLEXXA® injections?

In the FLEXX Trial across 588 patients, EUFLEXXA® showed statistically significant superiority over saline placebo on the primary endpoint of pain reduction during a standardized walking test through 26 weeks [1]. OARSI responder rates and WOMAC scores also favored the product [1]. Outcomes vary by patient and disease severity.

What are the long-term side effects of EUFLEXXA®?

The open-label extension safety study identified no significant long-term concerns beyond typical transient injection-site reactions through 52 weeks [1]. Repeated exposure has a theoretical potential to elicit an immune response, unconfirmed in clinical studies [1]. Review the full contraindications in current labeling before use.

What is the EUFLEXXA® J code?

The HCPCS code is J7323, “Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.” The procedure is reported under CPT 20610 without ultrasound guidance or 20611 with it [5]. Confirm current HCPCS and CPT guidance and payer policies with the applicable Medicare Administrative Contractor before billing, since coding guidance changes.

Trying to buy EUFLEXXA® online?

Medical Spa Rx stocks EUFLEXXA® for licensed practitioners, with add-to-cart ordering and secure checkout. Individual three-packs and bulk quantities are both available, so a clinic treating a handful of knee OA patients a month and one running a dedicated viscosupplementation service can order at the volume each actually needs.

Resources

1. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Seminars in Arthritis and Rheumatism. 2009. https://pubmed.ncbi.nlm.nih.gov/19539353/
2. Nicholls M, Manjoo A, Shaw P, Niazi F, Rosen J. A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid. Advances in Therapy. 2018;35(4):523–530. https://pmc.ncbi.nlm.nih.gov/articles/PMC5910459/
3. Webner D, Huang Y, Hummer CD 3rd. Intraarticular Hyaluronic Acid Preparations for Knee Osteoarthritis: Are Some Better Than Others?. Cartilage. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8808930/
4. S. Food and Drug Administration. Premarket Approval (PMA) P010029/S008 — EUFLEXXA (1% sodium hyaluronate). FDA. 2011. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P010029S008
5. Centers for Medicare & Medicaid Services. Billing and Coding: Intraarticular Knee Injections of Hyaluronan (Article A56157). CMS. Last Updated 06/18/2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56157&ver=15

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.